Nasdaq:US$18.36 (-0.86) | HKEX:HK$29.35 (-1.20) | AIM:£2.73 (-0.13)
Search Result
Previous Article   |   Next Article
Scientific Publications | 4 Jun 2021

ASCO 2021: Interim Analysis Results of Surufatinib in US Patients with Neuroendocrine Tumors (NETs)